Fig. 2From: Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progressionSerum SOST levels in control and rSOST treated mice. A decrease in SOST is apparent at both 4 and 8 weeks after the final proteoglycan injection (0 weeks). # = vs 0 week control, p < 0.05. * = vs 0 week rSOST, p < 0.05Back to article page